Cantargia publishes interim report for first quarter 2022

News provided by

Cantargia AB

23 May, 2022, 06:48 GMT

STOCKHOLM, May 23, 2022 /PRNewswire/ -- Cantargia AB's ("Cantargia") interim report for first quarter 2022 is now available on the company's web page www.cantargia.com/en/investors/financial-reports.

Significant events in the first quarter           

  • Clinical development of nadunolimab in pancreatic cancer (PDAC) was advanced by including nadunolimab in Pancreatic Cancer Action Network's (PanCAN) phase II/III clinical trial Precision Promise℠.          
  • The first patient with non-squamous non-small cell lung cancer (NSCLC) was treated in a new arm in CANFOUR, and the first patient with triple-negative breast cancer was treated in the TRIFOUR study.          
  • Positive safety data were reported from the CIRIFOUR study with nadunolimab and pembrolizumab.           
  • New promising results from non-GLP-regulated toxicology studies were reported for CAN10 and the phase I clinical trial was scheduled for early 2023.           
  • Positive preclinical efficacy data were presented for CAN10 in a model for systemic sclerosis at the 7th Systemic Sclerosis World Congress.           
  • An earlier decision by the European Patent Office (EPO) to reject an opposition to one of Cantargia's patents for treatment of solid tumors was appealed by a third party.          
  • The management team was strengthened by the recruitment of Dr. Roger Belusa as Interim Chief Medical Officer (CMO).

Significant events after the end of the period          

  • Cantargia announced that new clinical data for nadunolimab for PDAC and NSCLC patients in CANFOUR, and the first patients in CIRIFOUR, will be presented at ASCO in June.           
  • Cantargia announced that positive preclinical efficacy data for CAN10 in a model for atherosclerosis will be presented at the European Atherosclerosis Society Congress.

Financial information

First Quarter 2022      
  •  Net sales: SEK 0 M (0)                                               
  •  Operating loss: SEK -121.6 M (-73.2)                                               
  •  Loss after tax: SEK -117.5 M (-72.6)                                               
  •  Loss per share: before and after dilution, SEK -1.17 (-0.72)                                               
  •  Equity/assets ratio: 82 (94) per cent
  •  Cash and cash equivalents: SEK 205.7 M (176.4)
  •  Short-term investments: SEK 237.1 M (666.0)

In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on May 23, at 10:00 a.m. CET, where Göran Forsberg, CEO, and Bengt Jöndell, CFO, will present Cantargia and comment on the quarterly report for the first quarter 2022, followed by a Q&A-session.

The conference call can be followed at: https://tv.streamfabriken.com/cantargia-q1-2022

To attend through telephone, please dial-in at one of the numbers below:

SE: +46856642704
UK: +443333009265
US: +16467224904

The webcast will also be available on demand on Cantargia's corporate website: www.cantargia.com

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com

This is information that Cantargia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on May 23, 2022.

About Cantargia

Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The lead project, the antibody nadunolimab (CAN04), is being studied clinically in combination with chemotherapy or immune therapy in a series of clinical studies – CANFOUR, CIRIFOUR, CAPAFOUR, CESTAFOUR and TRIFOUR – with a primary focus on non-small cell lung cancer and pancreatic cancer. Positive interim data from the combination with chemotherapy indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second project, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/cantargia-ab/r/cantargia-publishes-interim-report-for-first-quarter-2022,c3571553

The following files are available for download: